AI assistant
Immunovant, Inc. — Director's Dealing 2021
Sep 14, 2021
31436_dirs_2021-09-14_95069350-7334-447a-91cc-2cc5d7fccc34.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2021-09-11
Reporting Person: Salzmann Peter (Director, Chief Executive Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-09-11 | Stock Option (right to buy) | $8.62 | A | 430700 | Acquired | 2030-05-14 | Common Stock (430700.0) | Direct |
| 2021-09-11 | Stock Option (right to buy) | $19.01 | D | 430700 | Disposed | 2030-05-14 | Common Stock (430700.0) | Direct |
| 2021-09-11 | Stock Option (right to buy) | $8.62 | A | 464700 | Acquired | 2031-03-19 | Common Stock (464700.0) | Direct |
| 2021-09-11 | Stock Option (right to buy) | $17.0 | D | 464700 | Disposed | 2031-03-19 | Common Stock (464700.0) | Direct |
Footnotes
F1: 25% of the shares underlying the options vested on May 15, 2021, and the remainder vested or vests in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.
F2: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.